Sang H Ahn, MD
Hematology/Oncology · Buena Park
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 32 years
- Graduated 1994
Offices
5 locations · USC Care Medical Group Inc · 1,378 clinicians in this group
Looking this up.
Hospitals listed: 058077 · 058131 · Keck Hospital of USC · Providence St. Jude Medical Center · USC Kenneth Norris Jr Cancer Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ahn’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A95562 · Current
Licensed to practise in California · since 2006 · expires 2027-11-30 · Seoul National University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Keck Hospital of USCLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of University of Southern California, which runs 4 hospitalsHome of USC Norris Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.79 (0.6 to 0.97), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.33 (2.15 to 8.51) · 2,872 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.25 (0.38 to 4.13) · 2,875 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.153, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.565, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.644, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.143, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.287, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 992 cases, Jan 2024 – Dec 2024
- Providence St. Jude Medical CenterFullerton, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.32, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.392, Oct 2024 – Sep 2025
See every measure and the patient survey for Keck Hospital of USC
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.6 to 0.97) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.33 (2.15 to 8.51) · 2,872 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.25 (0.38 to 4.13) · 2,875 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.153 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.565 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.644 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.143 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.287 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 992 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.47 to 1.79) · 3,513 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 178.09 (145.37 to 210.81) · 267 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 134 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.9 · 61 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 2,086 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0.03 to 0.39) · 6,677 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.12 to 0.48) · 7,784 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.38 (2.05 to 4.71) · 4,593 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.02 (0.97 to 3.08) · 2,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.52 (0.5 to 2.55) · 3,742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.61 (1.35 to 3.87) · 1,628 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.17 to 1.02) · 5,896 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 128 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.928 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 112 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 139 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.5 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.7 · 167 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -34.3 · 42 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.2 (2.8 to 6.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.7 (7.8 to 14.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.3 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.9 to 14.5) · 1,774 cases | No different | Jan 2022 – Dec 2024 |
What patients said (744 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Providence St. Jude Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.32 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.392 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.73 (0 to 1.63) · 1,738 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.07) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 141.84 (95.97 to 187.71) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 31 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.7 · 88 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 180 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 396 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 881 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 535 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,201 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.04 to 0.42) · 7,135 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.05 to 0.42) · 7,418 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.3 (0.42 to 4.18) · 1,649 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.78 (1.25 to 4.31) · 626 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.35 (0.9 to 3.81) · 1,493 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.88 (2.72 to 15.05) · 613 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.48 (1.05 to 7.91) · 581 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.56 (0.12 to 3) · 460 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.67) · 6,211 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 36 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.062 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.487 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.522 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 360 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 676 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 25.2 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0 · 437 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.7 · 930 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 1,415 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.7 to 7.5) · 261 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (10.1 to 16.6) · 261 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.5 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 170 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10.2 to 16.1) · 2,760 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 718 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$84,695
Medicare paid this office $84,695 for 512 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 345 | $47,468 | $69 |
| New patient visit (60+ min) | 64 | $7,842 | $123 |
| Short return visit (20+ min) | 112 | $7,584 | $49 |
| Long return visit (40+ min) | 49 | $7,181 | $104 |
| New patient visit (45+ min) | 66 | $5,822 | $88 |
See all 7 services
| Return visit (30+ min) | 345 | $47,468 | $69 |
| New patient visit (60+ min) | 64 | $7,842 | $123 |
| Short return visit (20+ min) | 112 | $7,584 | $49 |
| Long return visit (40+ min) | 49 | $7,181 | $104 |
| New patient visit (45+ min) | 66 | $5,822 | $88 |
| Telephone medical discussion with physician, 5-10 minutes | 156 | $5,327 | $25 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | $2,886 | $54 |
Who their Medicare patients are
512 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 22% · Women 63% · Also on Medicaid 76% · Health risk score 2.20. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 58% · Cancer 53% · Chronic kidney disease 38% · Coronary heart disease 36% · Depression 29% · COPD 25% · Heart failure 23% · Dementia 17% · Atrial fibrillation 16% · Stroke 7%.
The office billed $496,884, Medicare allowed $124,802 and paid $84,695; for 1,328 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 512 | 1,328 | 78 | 2.20 | $496,884 | $84,695 |
| 2023 | 490 | 1,402 | 78 | 2.37 | $520,130 | $92,988 |
| 2022 | 542 | 2,307 | 77 | 2.37 | $975,768 | $188,928 |
| 2021 | 557 | 2,588 | 77 | 2.49 | $1,161,820 | $243,606 |
| 2020 | 556 | 2,810 | 77 | 2.82 | $1,118,947 | $212,055 |
| 2019 | 604 | 2,991 | 77 | 2.83 | $878,330 | $224,180 |
| 2018 | 600 | 5,051 | 77 | 2.68 | $809,297 | $274,792 |
| 2017 | 646 | 9,467 | 77 | 2.74 | $816,741 | $378,957 |
| 2016 | 666 | 8,057 | 77 | 2.47 | $860,628 | $394,074 |
| 2015 | 622 | 8,449 | 77 | 2.23 | $779,387 | $358,900 |
| 2014 | 520 | 9,316 | 76 | 2.20 | $706,636 | $316,947 |
| 2013 | 624 | 18,467 | 76 | 2.46 | $1,170,382 | $448,704 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 337 | $46,346 | $70 |
| Long return visit (40+ min) | 98 | $17,096 | $113 |
| New patient visit (60+ min) | 68 | $9,802 | $144 |
| Telephone medical discussion with physician, 5-10 minutes | 205 | $8,644 | $27 |
| New patient visit (45+ min) | 62 | $6,196 | $100 |
| Short return visit (20+ min) | 42 | $1,941 | $41 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $1,344 | $45 |
| Short return visit | 30 | $1,310 | $24 |
2022: 9 services
| Return visit (30+ min) | 425 | $91,987 | $75 |
| Long return visit (40+ min) | 217 | $56,913 | $116 |
| New patient visit (60+ min) | 88 | $12,281 | $140 |
| Telephone medical discussion with physician, 21-30 minutes | 123 | $9,836 | $63 |
| Telephone medical discussion with physician, 11-20 minutes | 95 | $5,671 | $52 |
| New patient visit (45+ min) | 47 | $5,147 | $110 |
| Telephone medical discussion with physician, 5-10 minutes | 66 | $2,314 | $30 |
| Short return visit | 35 | $1,637 | $30 |
| Short return visit (20+ min) | 27 | $1,620 | $52 |
2021: 9 services
| Long return visit (40+ min) | 294 | $107,914 | $122 |
| Return visit (30+ min) | 353 | $71,929 | $75 |
| Telephone medical discussion with physician, 21-30 minutes | 206 | $28,239 | $79 |
| New patient visit (60+ min) | 117 | $16,357 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $6,065 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $4,462 | $86 |
| New patient visit (45+ min) | 41 | $3,256 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 36 | $2,147 | $49 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,385 | $87 |
2020: 11 services
| Return visit (30+ min) | 370 | $75,102 | $60 |
| Long return visit (40+ min) | 196 | $44,539 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 88 | $27,431 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 191 | $19,540 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $10,580 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $10,371 | $173 |
| New patient visit (60+ min) | 71 | $9,711 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $6,213 | $119 |
| New patient visit (45+ min) | 56 | $4,991 | $89 |
| Telephone medical discussion with physician, 11-20 minutes | 40 | $1,795 | $41 |
| Short return visit (20+ min) | 11 | $222 | $17 |
2019: 14 services
| Return visit (30+ min) | 288 | $53,705 | $59 |
| Return visit (30+ min) | 256 | $42,523 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $38,072 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $25,935 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $17,511 | $170 |
| Long return visit (40+ min) | 88 | $13,315 | $88 |
| Long return visit (40+ min) | 50 | $7,306 | $103 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,873 | $115 |
| New patient visit (45+ min) | 44 | $4,863 | $111 |
| New patient visit (60+ min) | 26 | $4,131 | $159 |
| New patient visit (60+ min) | 24 | $2,994 | $125 |
| Short return visit (20+ min) | 58 | $2,767 | $31 |
| New patient visit (45+ min) | 24 | $2,184 | $91 |
| Short return visit (20+ min) | 36 | $1,903 | $45 |
2018: 21 services
| Return visit (30+ min) | 280 | $59,433 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 181 | $56,496 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 115 | $25,208 | $62 |
| Return visit (30+ min) | 113 | $24,687 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 121 | $23,627 | $172 |
| Short return visit (20+ min) | 195 | $20,016 | $58 |
| Long return visit (40+ min) | 66 | $8,974 | $94 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $6,555 | $131 |
| Short return visit (20+ min) | 94 | $5,292 | $39 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,830 | $116 |
| New patient visit (60+ min) | 26 | $3,721 | $143 |
| New patient visit (45+ min) | 21 | $2,301 | $110 |
| New patient visit (45+ min) | 14 | $1,995 | $142 |
| Injection of drug or substance under skin or into muscle | 33 | $1,816 | $17 |
| Infusion into a vein for hydration, each additional hour | 23 | $1,699 | $12 |
| Insertion of needle into vein for collection of blood sample | 228 | $1,423 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $1,287 | $29 |
| New patient visit (30+ min) | 13 | $1,184 | $91 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,130 | $28 |
| Injection of additional new drug or substance into vein | 19 | $953 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $891 | $20 |
2017: 18 services
| Short return visit (20+ min) | 380 | $83,423 | $62 |
| Return visit (30+ min) | 307 | $64,448 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 173 | $48,488 | $89 |
| Administration of chemotherapy into vein, 1 hour or less | 55 | $38,026 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 132 | $34,127 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $11,195 | $172 |
| New patient visit (30+ min) | 111 | $9,751 | $88 |
| Infusion into a vein for hydration, each additional hour | 59 | $9,432 | $14 |
| Injection of drug or substance under skin or into muscle | 63 | $7,692 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $6,272 | $28 |
| Injection of additional new drug or substance into vein | 52 | $5,435 | $20 |
| Administration of chemotherapy into vein, each additional hour | 48 | $5,066 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $4,692 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 45 | $3,946 | $17 |
| Biopsy of bone marrow | 13 | $1,213 | $93 |
| Insertion of needle into vein for collection of blood sample | 177 | $897 | $3 |
| Injection, bevacizumab, 10 mg | 12 | $1 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $0 | None |
2016: 21 services
| Return visit (30+ min) | 364 | $107,150 | $88 |
| Short return visit (20+ min) | 294 | $60,018 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 195 | $57,406 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $45,625 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $24,225 | $88 |
| Injection of drug or substance under skin or into muscle | 92 | $11,141 | $22 |
| Infusion into a vein for hydration, each additional hour | 70 | $11,047 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 68 | $10,008 | $27 |
| Administration of chemotherapy into vein, each additional hour | 53 | $8,863 | $25 |
| New patient visit (30+ min) | 89 | $7,982 | $90 |
| Injection of additional new drug or substance into vein | 61 | $7,049 | $20 |
| New patient visit (45+ min) | 49 | $6,681 | $136 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $6,035 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,986 | $116 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 55 | $4,623 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,334 | $167 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,244 | $55 |
| Insertion of needle into vein for collection of blood sample | 170 | $850 | $3 |
| Injection, bevacizumab, 10 mg | 11 | $1 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $0 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $0 | None |
2015: 23 services
| Return visit (30+ min) | 335 | $118,129 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 229 | $69,789 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $33,372 | $121 |
| Short return visit (20+ min) | 162 | $32,825 | $62 |
| Injection of drug or substance under skin or into muscle | 87 | $11,334 | $22 |
| New patient visit (45+ min) | 74 | $10,088 | $136 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 263 | $8,877 | $10 |
| Infusion into a vein for hydration, each additional hour | 63 | $8,377 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 59 | $7,789 | $27 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 65 | $7,608 | $115 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $6,774 | $56 |
| Administration of chemotherapy into vein, each additional hour | 49 | $6,361 | $25 |
| Injection of additional new drug or substance into vein | 53 | $6,143 | $20 |
| New patient visit (30+ min) | 66 | $6,097 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,747 | $170 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 41 | $3,098 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,361 | $87 |
| Insertion of needle into vein for collection of blood sample | 281 | $2,129 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $43 | None |
| Infusion, normal saline solution, 250 cc | 14 | $8 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $1 | None |
| Injection, bevacizumab, 10 mg | 11 | $1 | None |
| Injection, carboplatin, 50 mg | 15 | $0 | None |
2014: 25 services
| Return visit (30+ min) | 282 | $104,829 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 166 | $48,127 | $60 |
| Short return visit (20+ min) | 189 | $34,945 | $63 |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $29,667 | $119 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 286 | $9,890 | $10 |
| Infusion into a vein for hydration, each additional hour | 87 | $9,507 | $13 |
| New patient visit (45+ min) | 60 | $8,460 | $141 |
| Injection of drug or substance under skin or into muscle | 87 | $7,945 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $7,528 | $27 |
| Administration of chemotherapy into vein, each additional hour | 47 | $6,801 | $25 |
| New patient visit (30+ min) | 65 | $6,029 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $5,872 | $115 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $5,746 | $55 |
| Injection of additional new drug or substance into vein | 50 | $5,723 | $20 |
| Administration of additional new drug or substance into vein using push technique | 22 | $4,753 | $55 |
| Administration of chemotherapy into vein using push technique | 14 | $3,219 | $98 |
| Infusion into a vein for hydration, 31-60 minutes | 35 | $2,976 | $50 |
| Biopsy of bone marrow | 14 | $2,062 | $147 |
| Insertion of needle into vein for collection of blood sample | 238 | $1,952 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $1,508 | $16 |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $67 | None |
| Infusion, normal saline solution , 1000 cc | 19 | $39 | None |
| Infusion, normal saline solution, 250 cc | 53 | $33 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 11 | $19 | None |
| Injection, fluorouracil, 500 mg | 19 | $7 | None |
2013: 33 services
| Return visit (30+ min) | 229 | $97,058 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 294 | $64,925 | $58 |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $45,793 | $128 |
| Short return visit (20+ min) | 190 | $45,443 | $61 |
| Administration of chemotherapy into vein, each additional hour | 60 | $13,751 | $27 |
| Infusion into a vein for hydration, each additional hour | 99 | $13,621 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 269 | $12,095 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 73 | $11,976 | $28 |
| New patient visit (45+ min) | 84 | $11,568 | $138 |
| Administration of additional new drug or substance into vein using push technique | 30 | $10,980 | $55 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $10,135 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 87 | $9,472 | $109 |
| New patient visit (30+ min) | 76 | $6,787 | $89 |
| Injection of drug or substance under skin or into muscle | 68 | $6,572 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 61 | $6,433 | $19 |
| Injection of additional new drug or substance into vein | 58 | $5,913 | $20 |
| Administration of chemotherapy into vein using push technique | 11 | $5,493 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,977 | $85 |
| Infusion into a vein for hydration, 31-60 minutes | 48 | $3,871 | $52 |
| Insertion of needle into vein for collection of blood sample | 292 | $3,736 | $3 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,630 | $165 |
| Biopsy of bone marrow | 21 | $3,250 | $148 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $2,919 | $66 |
| Injection, leucovorin calcium, per 50 mg | 20 | $1,474 | None |
| Irrigation of implanted venous access drug delivery device | 13 | $1,132 | $23 |
| Injection, granisetron hydrochloride, 100 mcg | 30 | $415 | None |
| Injection, fluorouracil, 500 mg | 19 | $374 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $133 | None |
| Infusion, normal saline solution, 250 cc | 90 | $96 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $90 | None |
| Infusion, normal saline solution , 1000 cc | 32 | $83 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $20 | None |
| Injection, heparin sodium, per 1000 units | 22 | $17 | None |
Medicaid work
$8,399 in 2024
Medicaid paid $8,399 for 263 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 196 | $8,296 |
| CARCINOEMBRYONIC ANTIGEN | 16 | $43 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 26 | $35 |
| COMPREHENSIVE METABOLIC PANEL | 25 | $24 |
| 2024 | 263 | 4 | 25 | $8,399 |
| 2023 | 360 | 2 | 30 | $14,491 |
| 2022 | 447 | 4 | 48 | $20,562 |
| 2021 | 185 | 2 | 18 | $13,691 |
| 2020 | 300 | 2 | 40 | $12,929 |
| 2019 | 561 | 5 | 39 | $18,671 |
| 2018 | 1,234 | 11 | 59 | $23,705 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 286 | $13,756 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 74 | $735 |
2022
| Return visit (30+ min) | 371 | $16,939 |
| Long return visit (40+ min) | 48 | $2,750 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 16 | $665 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 12 | $208 |
2021
| Return visit (30+ min) | 115 | $7,536 |
| Long return visit (40+ min) | 70 | $6,155 |
2020
| Return visit (30+ min) | 285 | $12,418 |
| Service | 15 | $512 |
2019
| Return visit (30+ min) | 433 | $16,642 |
| Service | 30 | $1,023 |
| COMPREHENSIVE METABOLIC PANEL | 41 | $455 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 42 | $344 |
| Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) | 15 | $207 |
2018
| Return visit (30+ min) | 507 | $11,090 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 165 | $5,547 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 62 | $2,545 |
| Short return visit (20+ min) | 176 | $1,618 |
| Service | 35 | $1,194 |
| COMPREHENSIVE METABOLIC PANEL | 70 | $748 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 72 | $564 |
| Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) | 14 | $167 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 14 | $132 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 61 | $102 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 58 | $0 |
Drugs they prescribed that Part D paid
$8,455,302
Pharmacies billed $8,455,302 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (21 of 1,278) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
637 generic and fewer than 11 brand-name prescriptions · $8,455,302 in drug cost · 16 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 75 | $1,174,161 | $15,655 |
| Cabometyx | 34 | $796,877 | $23,438 |
| Erleada | 53 | $768,123 | $14,493 |
| Promacta | 78 | $728,634 | $9,341 |
| Tasigna | 40 | $700,653 | $17,516 |
See all 29 drugs
| Tagrisso | 75 | $1,174,161 | $15,655 |
| Cabometyx | 34 | $796,877 | $23,438 |
| Erleada | 53 | $768,123 | $14,493 |
| Promacta | 78 | $728,634 | $9,341 |
| Tasigna | 40 | $700,653 | $17,516 |
| Revlimid | 46 | $635,812 | $13,822 |
| Lenvima | 21 | $490,123 | $23,339 |
| Lonsurf | 41 | $396,888 | $9,680 |
| Xtandi | 25 | $335,354 | $13,414 |
| Fruzaqla | 11 | $265,002 | $24,091 |
| Verzenio | 18 | $245,247 | $13,625 |
| Lenalidomide | 16 | $165,068 | $10,317 |
| Abiraterone Acetate | 53 | $138,382 | $2,611 |
| Everolimus | 12 | $105,715 | $8,810 |
| Aranesp | 16 | $69,432 | $4,340 |
| Procrit | 29 | $39,739 | $1,370 |
| Retacrit | 23 | $15,800 | $687 |
| Exemestane | 14 | $1,716 | $123 |
| Letrozole | 83 | $1,178 | $14 |
| Hydroxyurea | 35 | $767 | $22 |
| Sodium Chloride | 22 | $734 | $33 |
| Anastrozole | 83 | $724 | $9 |
| Deferasirox | 16 | $574 | $36 |
| Tamoxifen Citrate | 22 | $332 | $15 |
| Alendronate | 20 | $179 | $9 |
| Dexamethasone | 12 | $162 | $14 |
| Levothyroxine | 41 | $121 | $3 |
| Pantoprazole | 13 | $98 | $8 |
| Prednisone | 37 | $66 | $2 |
Year by year
| 2024 | 1,278 | 213 | 2% (21) | None | $8,455,302 |
| 2023 | 1,267 | 250 | 2% (30) | 49% | $8,260,968 |
| 2022 | 1,547 | 299 | 3% (43) | None | $6,807,285 |
| 2021 | 1,385 | 259 | 3% (36) | None | $6,500,555 |
| 2020 | 1,501 | 263 | 4% (58) | None | $6,802,375 |
| 2019 | 1,814 | 289 | 6% (104) | 35% | $5,854,231 |
| 2018 | 2,273 | 275 | 7% (167) | None | $5,915,904 |
| 2017 | 3,286 | 289 | 5% (151) | 42% | $6,352,424 |
| 2016 | 4,080 | 280 | 3% (101) | 43% | $5,332,456 |
| 2015 | 3,504 | 303 | 6% (206) | 39% | $4,129,805 |
| 2014 | 2,997 | 291 | 7% (218) | 38% | $2,611,299 |
| 2013 | 2,492 | 275 | 9% (222) | 22% | $1,658,206 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Tagrisso | 78 | $1,344,000 | $17,231 |
| Lenvima | 37 | $968,183 | $26,167 |
| Tasigna | 46 | $789,015 | $17,152 |
| Promacta | 72 | $708,115 | $9,835 |
| Erleada | 34 | $550,809 | $16,200 |
| Revlimid | 33 | $460,182 | $13,945 |
| Alecensa | 23 | $424,791 | $18,469 |
| Cabometyx | 14 | $347,275 | $24,805 |
| Inlyta | 13 | $286,362 | $22,028 |
| Lonsurf | 24 | $248,897 | $10,371 |
| Lynparza | 18 | $237,786 | $13,210 |
| Lenalidomide | 19 | $230,875 | $12,151 |
| Verzenio | 13 | $182,525 | $14,040 |
| Kisqali | 12 | $168,734 | $14,061 |
| Everolimus | 12 | $115,330 | $9,611 |
| Deferiprone (3 Times A Day) | 12 | $102,022 | $8,502 |
| Procrit | 65 | $95,442 | $1,468 |
| Abiraterone Acetate | 58 | $88,935 | $1,533 |
| Creon | 13 | $12,774 | $983 |
| Exemestane | 19 | $6,548 | $345 |
| Anastrozole | 70 | $3,142 | $45 |
| Letrozole | 61 | $2,474 | $41 |
| Hydroxyurea | 51 | $1,334 | $26 |
| Imatinib Mesylate | 15 | $1,317 | $88 |
| Sodium Chloride | 24 | $1,261 | $53 |
| Deferasirox | 14 | $971 | $69 |
| Tamoxifen Citrate | 22 | $882 | $40 |
| Alendronate | 31 | $746 | $24 |
| Levothyroxine | 39 | $639 | $16 |
| Hydrocodone-Acetaminophen | 14 | $596 | $43 |
| Prednisone | 42 | $291 | $7 |
| Pantoprazole | 15 | $267 | $18 |
| Gabapentin | 11 | $236 | $21 |
| Dexamethasone | 24 | $129 | $5 |
2022: 38 drugs
| Tagrisso | 58 | $959,675 | $16,546 |
| Tasigna | 54 | $896,412 | $16,600 |
| Promacta | 60 | $542,732 | $9,046 |
| Revlimid | 38 | $516,196 | $13,584 |
| Lenvima | 16 | $357,364 | $22,335 |
| Lonsurf | 26 | $278,656 | $10,718 |
| Erleada | 18 | $268,994 | $14,944 |
| Alecensa | 13 | $228,145 | $17,550 |
| Imbruvica | 14 | $216,759 | $15,483 |
| Xtandi | 15 | $212,607 | $14,174 |
| Inlyta | 11 | $187,173 | $17,016 |
| Abiraterone Acetate | 43 | $170,281 | $3,960 |
| Zytiga | 11 | $130,477 | $11,862 |
| Everolimus | 11 | $88,135 | $8,012 |
| Procrit | 35 | $54,208 | $1,549 |
| Eliquis | 26 | $15,863 | $610 |
| Exemestane | 43 | $8,523 | $198 |
| Retacrit | 11 | $5,192 | $472 |
| Anastrozole | 165 | $3,953 | $24 |
| Letrozole | 95 | $2,496 | $26 |
| Imatinib Mesylate | 20 | $1,906 | $95 |
| Tamoxifen Citrate | 40 | $1,799 | $45 |
| Hydroxyurea | 50 | $1,425 | $28 |
| Levothyroxine | 88 | $1,190 | $14 |
| Megestrol Acetate | 20 | $1,086 | $54 |
| Hydrocodone-Acetaminophen | 28 | $756 | $27 |
| Dexamethasone | 32 | $578 | $18 |
| Loperamide | 22 | $545 | $25 |
| Prednisone | 61 | $493 | $8 |
| Alendronate | 27 | $445 | $16 |
| Acyclovir | 13 | $248 | $19 |
| Gabapentin | 18 | $208 | $12 |
| Sulfamethoxazole-Trimethoprim | 15 | $148 | $10 |
| Ondansetron | 11 | $114 | $10 |
| Pantoprazole | 14 | $104 | $7 |
| Omeprazole | 13 | $67 | $5 |
| Zolpidem | 14 | $37 | $3 |
| Folic Acid | 13 | $29 | $2 |
2021: 33 drugs
| Revlimid | 93 | $1,246,788 | $13,406 |
| Tagrisso | 58 | $946,436 | $16,318 |
| Tasigna | 51 | $752,606 | $14,757 |
| Xtandi | 41 | $511,558 | $12,477 |
| Promacta | 51 | $440,526 | $8,638 |
| Lenvima | 17 | $352,729 | $20,749 |
| Erleada | 21 | $298,998 | $14,238 |
| Tabrecta | 14 | $278,933 | $19,924 |
| Lonsurf | 24 | $192,601 | $8,025 |
| Ninlaro | 20 | $185,089 | $9,254 |
| Everolimus | 20 | $184,009 | $9,200 |
| Zytiga | 13 | $149,445 | $11,496 |
| Procrit | 59 | $105,107 | $1,781 |
| Abiraterone Acetate | 27 | $72,429 | $2,683 |
| Eliquis | 28 | $14,807 | $529 |
| Exemestane | 52 | $9,047 | $174 |
| Imatinib Mesylate | 14 | $7,561 | $540 |
| Anastrozole | 132 | $3,165 | $24 |
| Tamoxifen Citrate | 48 | $1,749 | $36 |
| Letrozole | 61 | $1,616 | $26 |
| Hydroxyurea | 46 | $1,466 | $32 |
| Dexamethasone | 72 | $1,334 | $19 |
| Levothyroxine | 78 | $1,281 | $16 |
| Deferasirox | 17 | $1,263 | $74 |
| Hydrocodone-Acetaminophen | 24 | $950 | $40 |
| Megestrol Acetate | 18 | $737 | $41 |
| Sucralfate | 12 | $463 | $39 |
| Prednisone | 39 | $343 | $9 |
| Venlafaxine Hcl Er | 12 | $339 | $28 |
| Sodium Chloride | 12 | $335 | $28 |
| Pantoprazole | 12 | $97 | $8 |
| Folic Acid | 16 | $40 | $2 |
| Hydrochlorothiazide | 12 | $33 | $3 |
2020: 33 drugs
| Tagrisso | 83 | $1,327,627 | $15,996 |
| Revlimid | 96 | $1,262,126 | $13,147 |
| Tasigna | 45 | $665,342 | $14,785 |
| Promacta | 53 | $417,108 | $7,870 |
| Xtandi | 26 | $326,111 | $12,543 |
| Lenvima | 15 | $288,664 | $19,244 |
| Zytiga | 21 | $228,504 | $10,881 |
| Procrit | 84 | $197,788 | $2,355 |
| Erleada | 13 | $174,511 | $13,424 |
| Imbruvica | 12 | $171,949 | $14,329 |
| Ibrance | 13 | $170,552 | $13,119 |
| Everolimus | 13 | $149,409 | $11,493 |
| Ninlaro | 12 | $132,937 | $11,078 |
| Abiraterone Acetate | 25 | $97,996 | $3,920 |
| Erlotinib | 21 | $71,202 | $3,391 |
| Imatinib Mesylate | 40 | $70,021 | $1,751 |
| Exemestane | 57 | $10,666 | $187 |
| Eliquis | 16 | $7,595 | $475 |
| Anastrozole | 135 | $3,165 | $23 |
| Hydroxyurea | 52 | $1,979 | $38 |
| Dexamethasone | 73 | $1,683 | $23 |
| Tamoxifen Citrate | 54 | $1,677 | $31 |
| Letrozole | 69 | $1,659 | $24 |
| Hydrocodone-Acetaminophen | 42 | $1,204 | $29 |
| Levothyroxine | 51 | $1,000 | $20 |
| Megestrol Acetate | 22 | $880 | $40 |
| Sucralfate | 13 | $718 | $55 |
| Duloxetine | 18 | $404 | $22 |
| Triamcinolone Acetonide | 11 | $229 | $21 |
| Pantoprazole | 27 | $206 | $8 |
| Prednisone | 26 | $183 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $74 | $7 |
| Hydrochlorothiazide | 14 | $37 | $3 |
2019: 38 drugs
| Tagrisso | 75 | $1,162,043 | $15,494 |
| Revlimid | 90 | $1,107,235 | $12,303 |
| Lenvima | 26 | $480,776 | $18,491 |
| Promacta | 44 | $361,545 | $8,217 |
| Tasigna | 24 | $358,099 | $14,921 |
| Procrit | 88 | $268,596 | $3,052 |
| Tarceva | 23 | $202,348 | $8,798 |
| Ibrance | 15 | $189,397 | $12,626 |
| Xtandi | 15 | $182,419 | $12,161 |
| Sprycel | 11 | $160,892 | $14,627 |
| Lonsurf | 17 | $160,528 | $9,443 |
| Zytiga | 14 | $148,695 | $10,621 |
| Xgeva | 24 | $55,497 | $2,312 |
| Imatinib Mesylate | 40 | $37,933 | $948 |
| Exemestane | 53 | $16,552 | $312 |
| Eliquis | 29 | $12,918 | $445 |
| Anastrozole | 155 | $3,578 | $23 |
| Tamoxifen Citrate | 64 | $2,029 | $32 |
| Letrozole | 76 | $1,554 | $20 |
| Hydroxyurea | 34 | $1,519 | $45 |
| Hydrocodone-Acetaminophen | 64 | $1,508 | $24 |
| Dexamethasone | 82 | $1,498 | $18 |
| Megestrol Acetate | 36 | $1,443 | $40 |
| Levothyroxine | 58 | $1,145 | $20 |
| Ondansetron | 61 | $819 | $13 |
| Prednisone | 59 | $604 | $10 |
| Sucralfate | 14 | $509 | $36 |
| Triamcinolone Acetonide | 17 | $346 | $20 |
| Acyclovir | 22 | $326 | $15 |
| Pantoprazole | 41 | $298 | $7 |
| Nystatin | 26 | $208 | $8 |
| Sulfamethoxazole-Trimethoprim | 20 | $194 | $10 |
| Oxycodone | 13 | $172 | $13 |
| Levofloxacin | 25 | $169 | $7 |
| Alendronate | 17 | $156 | $9 |
| Hydrocortisone | 16 | $93 | $6 |
| Zolpidem | 11 | $76 | $7 |
| Hydrochlorothiazide | 14 | $32 | $2 |
2018: 53 drugs
| Revlimid | 53 | $619,924 | $11,697 |
| Tagrisso | 38 | $587,873 | $15,470 |
| Ibrance | 39 | $460,984 | $11,820 |
| Jadenu | 33 | $392,646 | $11,898 |
| Tarceva | 42 | $351,435 | $8,368 |
| Promacta | 41 | $331,460 | $8,084 |
| Procrit | 86 | $263,188 | $3,060 |
| Tasigna | 19 | $256,014 | $13,474 |
| Lenvima | 15 | $250,454 | $16,697 |
| Sprycel | 19 | $224,734 | $11,828 |
| Imbruvica | 16 | $188,564 | $11,785 |
| Zytiga | 18 | $186,877 | $10,382 |
| Sutent | 11 | $164,727 | $14,975 |
| Gleevec | 13 | $133,453 | $10,266 |
| Imatinib Mesylate | 31 | $132,114 | $4,262 |
| Xgeva | 50 | $115,794 | $2,316 |
| Nplate | 11 | $97,955 | $8,905 |
| Subsys | 11 | $97,575 | $8,870 |
| Exemestane | 37 | $12,074 | $326 |
| Eliquis | 20 | $8,391 | $420 |
| Anagrelide | 11 | $8,128 | $739 |
| Creon | 13 | $6,996 | $538 |
| Anastrozole | 222 | $4,234 | $19 |
| Hydrocodone-Acetaminophen | 118 | $3,804 | $32 |
| Megestrol Acetate | 51 | $1,720 | $34 |
| Letrozole | 83 | $1,374 | $17 |
| Hydroxyurea | 31 | $1,333 | $43 |
| Ondansetron | 52 | $1,288 | $25 |
| Dexamethasone | 86 | $1,268 | $15 |
| Levothyroxine | 72 | $1,231 | $17 |
| Tamoxifen Citrate | 47 | $1,223 | $26 |
| Esomeprazole Magnesium | 13 | $1,014 | $78 |
| Duloxetine | 11 | $829 | $75 |
| Fentanyl | 11 | $739 | $67 |
| Granisetron | 27 | $635 | $24 |
| Prednisone | 47 | $544 | $12 |
| Loperamide | 32 | $524 | $16 |
| Nystatin | 28 | $392 | $14 |
| Levofloxacin | 17 | $352 | $21 |
| Sodium Chloride | 29 | $337 | $12 |
| Alendronate | 28 | $256 | $9 |
| Triamcinolone Acetonide | 19 | $248 | $13 |
| Sulfamethoxazole-Trimethoprim | 26 | $238 | $9 |
| Omeprazole | 26 | $190 | $7 |
| Zolpidem | 24 | $179 | $7 |
| Acyclovir | 11 | $146 | $13 |
| Hydrocortisone | 12 | $118 | $10 |
| Pantoprazole | 17 | $110 | $6 |
| Trazodone | 12 | $86 | $7 |
| Dexamethasone Sodium Phosphate | 21 | $72 | $3 |
| Diphenhydramine | 39 | $60 | $2 |
| Furosemide | 19 | $43 | $2 |
| Hydrochlorothiazide | 12 | $23 | $2 |
2017: 69 drugs
| Revlimid | 69 | $771,456 | $11,181 |
| Tarceva | 55 | $431,755 | $7,850 |
| Ibrance | 34 | $376,333 | $11,069 |
| Xgeva | 149 | $328,111 | $2,202 |
| Avastin | 72 | $302,142 | $4,196 |
| Sutent | 24 | $299,481 | $12,478 |
| Promacta | 40 | $244,204 | $6,105 |
| Sprycel | 23 | $228,615 | $9,940 |
| Procrit | 98 | $227,500 | $2,321 |
| Jadenu | 20 | $199,624 | $9,981 |
| Keytruda | 19 | $179,329 | $9,438 |
| Imatinib Mesylate | 31 | $177,139 | $5,714 |
| Nplate | 22 | $173,622 | $7,892 |
| Gleevec | 17 | $171,176 | $10,069 |
| Tasigna | 13 | $160,990 | $12,384 |
| Imbruvica | 12 | $135,900 | $11,325 |
| Xtandi | 12 | $124,021 | $10,335 |
| Herceptin | 30 | $121,462 | $4,049 |
| Alimta | 17 | $115,471 | $6,792 |
| Exjade | 21 | $114,245 | $5,440 |
| Cyramza | 14 | $103,106 | $7,365 |
| Perjeta | 17 | $85,420 | $5,025 |
| Velcade | 17 | $79,647 | $4,685 |
| Opdivo | 12 | $62,978 | $5,248 |
| Tykerb | 12 | $50,890 | $4,241 |
| Rituxan | 18 | $50,405 | $2,800 |
| Lupron Depot | 18 | $44,868 | $2,493 |
| Faslodex | 16 | $39,170 | $2,448 |
| Docetaxel | 17 | $13,780 | $811 |
| Exemestane | 33 | $13,106 | $397 |
| Gemcitabine | 13 | $12,082 | $929 |
| Oxaliplatin | 40 | $6,075 | $152 |
| Anagrelide | 12 | $4,342 | $362 |
| Anastrozole | 213 | $3,394 | $16 |
| Paclitaxel | 16 | $2,748 | $172 |
| Hydrocodone-Acetaminophen | 114 | $2,541 | $22 |
| Sodium Chloride | 258 | $2,416 | $9 |
| Granisetron | 122 | $2,374 | $19 |
| Irinotecan | 12 | $2,338 | $195 |
| Letrozole | 128 | $1,371 | $11 |
| Cabergoline | 11 | $1,341 | $122 |
| Zoledronic Acid | 14 | $1,268 | $91 |
| Megestrol Acetate | 35 | $1,230 | $35 |
| Carboplatin | 19 | $1,125 | $59 |
| Dexamethasone | 103 | $927 | $9 |
| Hydroxyurea | 22 | $884 | $40 |
| Tamoxifen Citrate | 38 | $870 | $23 |
| Betamethasone Dipropionate | 17 | $779 | $46 |
| Levothyroxine | 49 | $768 | $16 |
| Acyclovir | 30 | $620 | $21 |
| Ondansetron | 45 | $507 | $11 |
| Dexamethasone Sodium Phosphate | 152 | $490 | $3 |
| Loperamide | 25 | $478 | $19 |
| Granisetron | 31 | $466 | $15 |
| Oxycodone-Acetaminophen | 12 | $466 | $39 |
| Levofloxacin | 33 | $460 | $14 |
| Bicalutamide | 21 | $414 | $20 |
| Diphenhydramine | 199 | $353 | $2 |
| Pamidronate Disodium | 13 | $347 | $27 |
| Sulfamethoxazole-Trimethoprim | 31 | $274 | $9 |
| Potassium Chloride | 13 | $245 | $19 |
| Alendronate | 49 | $232 | $5 |
| Gabapentin | 17 | $188 | $11 |
| Dexamethasone Sodium Phosphate | 18 | $160 | $9 |
| Zolpidem | 16 | $116 | $7 |
| Omeprazole | 14 | $114 | $8 |
| Dextrose in Water | 42 | $112 | $3 |
| Furosemide | 16 | $75 | $5 |
| Lactulose | 11 | $67 | $6 |
2016: 73 drugs
| Revlimid | 63 | $598,754 | $9,504 |
| Gleevec | 39 | $392,834 | $10,073 |
| Avastin | 80 | $366,485 | $4,581 |
| Tarceva | 48 | $344,453 | $7,176 |
| Ibrance | 26 | $273,403 | $10,515 |
| Procrit | 124 | $268,826 | $2,168 |
| Xgeva | 127 | $255,856 | $2,015 |
| Nplate | 27 | $199,780 | $7,399 |
| Sprycel | 23 | $198,191 | $8,617 |
| Nexavar | 13 | $195,019 | $15,001 |
| Herceptin | 43 | $184,071 | $4,281 |
| Alimta | 25 | $148,361 | $5,934 |
| Promacta | 39 | $143,141 | $3,670 |
| Tasigna | 13 | $135,748 | $10,442 |
| Opdivo | 15 | $103,087 | $6,872 |
| Velcade | 19 | $101,070 | $5,319 |
| Jadenu | 14 | $99,306 | $7,093 |
| Gilotrif | 11 | $80,472 | $7,316 |
| Exjade | 18 | $58,698 | $3,261 |
| Neupogen | 43 | $53,689 | $1,249 |
| Oxaliplatin | 64 | $48,748 | $762 |
| Docetaxel | 27 | $38,221 | $1,416 |
| Faslodex | 16 | $34,047 | $2,128 |
| Emend | 34 | $21,484 | $632 |
| Cyclophosphamide | 26 | $20,620 | $793 |
| Aloxi | 42 | $20,091 | $478 |
| Gemcitabine | 27 | $10,605 | $393 |
| Creon | 18 | $10,196 | $566 |
| Exemestane | 25 | $9,060 | $362 |
| Sodium Chloride | 555 | $4,688 | $8 |
| Granisetron | 175 | $4,627 | $26 |
| Eliquis | 11 | $4,021 | $366 |
| Paclitaxel | 30 | $3,494 | $116 |
| Nexium | 12 | $3,030 | $253 |
| Hydrocodone-Acetaminophen | 84 | $2,930 | $35 |
| Cisplatin | 25 | $2,516 | $101 |
| Anastrozole | 181 | $2,471 | $14 |
| Epirubicin | 18 | $1,985 | $110 |
| Dexamethasone Sodium Phosphate | 152 | $1,784 | $12 |
| Zoledronic Acid | 22 | $1,771 | $81 |
| Carboplatin | 36 | $1,682 | $47 |
| Doxorubicin | 24 | $1,651 | $69 |
| Esomeprazole Magnesium | 13 | $1,465 | $113 |
| Letrozole | 139 | $1,348 | $10 |
| Megestrol Acetate | 50 | $1,221 | $24 |
| Hydroxyurea | 41 | $1,147 | $28 |
| Anagrelide | 19 | $1,057 | $56 |
| Pamidronate Disodium | 26 | $833 | $32 |
| Dexamethasone | 101 | $770 | $8 |
| Tamoxifen Citrate | 26 | $757 | $29 |
| Diphenhydramine | 262 | $745 | $3 |
| Ondansetron | 27 | $665 | $25 |
| Levothyroxine | 41 | $623 | $15 |
| Cabergoline | 11 | $557 | $51 |
| Levofloxacin | 43 | $534 | $12 |
| Methylprednisolone | 12 | $529 | $44 |
| Ibandronate | 12 | $520 | $43 |
| Dexamethasone Sodium Phosphate | 137 | $512 | $4 |
| Dextrose 5%-0.9% Nacl | 18 | $430 | $24 |
| Gabapentin | 31 | $363 | $12 |
| Acyclovir | 34 | $351 | $10 |
| Sulfamethoxazole-Trimethoprim | 42 | $304 | $7 |
| Prednisone | 33 | $272 | $8 |
| Loperamide | 12 | $233 | $19 |
| Alendronate | 40 | $223 | $6 |
| Zolpidem | 26 | $199 | $8 |
| Dextrose in Water | 46 | $171 | $4 |
| Hydroxyzine | 13 | $161 | $12 |
| Valacyclovir | 13 | $126 | $10 |
| Warfarin | 25 | $121 | $5 |
| Omeprazole | 14 | $75 | $5 |
| Pantoprazole | 12 | $70 | $6 |
| Sertraline | 12 | $43 | $4 |
2015: 69 drugs
| Revlimid | 52 | $467,740 | $8,995 |
| Avastin | 98 | $465,391 | $4,749 |
| Gleevec | 39 | $360,901 | $9,254 |
| Procrit | 113 | $245,004 | $2,168 |
| Sprycel | 26 | $205,263 | $7,895 |
| Nexavar | 14 | $179,803 | $12,843 |
| Xgeva | 91 | $170,559 | $1,874 |
| Nplate | 26 | $166,743 | $6,413 |
| Tasigna | 14 | $134,832 | $9,631 |
| Velcade | 20 | $123,673 | $6,184 |
| Erbitux | 15 | $118,916 | $7,928 |
| Imbruvica | 11 | $105,171 | $9,561 |
| Zytiga | 12 | $97,055 | $8,088 |
| Gilotrif | 13 | $87,864 | $6,759 |
| Herceptin | 15 | $78,242 | $5,216 |
| Alimta | 15 | $75,576 | $5,038 |
| Rituxan | 14 | $67,205 | $4,800 |
| Cyramza | 16 | $49,362 | $3,085 |
| Docetaxel | 32 | $46,552 | $1,455 |
| Oxaliplatin | 53 | $44,130 | $833 |
| Aloxi | 68 | $37,973 | $558 |
| Faslodex | 11 | $36,902 | $3,355 |
| Neupogen | 25 | $32,249 | $1,290 |
| Exjade | 15 | $30,448 | $2,030 |
| Gemcitabine | 40 | $23,103 | $578 |
| Emend | 22 | $12,443 | $566 |
| Creon | 21 | $8,762 | $417 |
| Oxycontin | 11 | $7,070 | $643 |
| Exemestane | 16 | $6,537 | $409 |
| Leucovorin | 30 | $5,229 | $174 |
| Irinotecan | 30 | $5,041 | $168 |
| Hydrocodone-Acetaminophen | 124 | $4,815 | $39 |
| Nexium | 19 | $4,760 | $251 |
| Granisetron | 141 | $4,705 | $33 |
| Sodium Chloride | 359 | $3,667 | $10 |
| Carboplatin | 54 | $3,363 | $62 |
| Anastrozole | 137 | $2,271 | $17 |
| Paclitaxel | 27 | $2,265 | $84 |
| Fentanyl | 23 | $1,816 | $79 |
| Dexamethasone Sodium Phosphate | 224 | $1,362 | $6 |
| Duloxetine | 14 | $1,325 | $95 |
| Granisetron | 32 | $1,060 | $33 |
| Fluorouracil | 30 | $1,053 | $35 |
| Megestrol Acetate | 42 | $995 | $24 |
| Ondansetron | 32 | $992 | $31 |
| Levofloxacin | 48 | $977 | $20 |
| Letrozole | 106 | $955 | $9 |
| Cisplatin | 14 | $857 | $61 |
| Morphine Sulfate Er | 13 | $856 | $66 |
| Dexamethasone Sodium Phosphate | 54 | $783 | $15 |
| Diphenhydramine | 181 | $742 | $4 |
| Levothyroxine | 45 | $710 | $16 |
| Hydroxyurea | 35 | $691 | $20 |
| Dexamethasone | 79 | $646 | $8 |
| Pamidronate Disodium | 19 | $646 | $34 |
| Ibandronate | 12 | $616 | $51 |
| Tamoxifen Citrate | 24 | $606 | $25 |
| Loperamide | 26 | $419 | $16 |
| Valacyclovir | 12 | $395 | $33 |
| Dextrose 5%-0.9% Nacl | 14 | $388 | $28 |
| Warfarin | 43 | $349 | $8 |
| Amoxicillin-Clavulanate Potass | 15 | $345 | $23 |
| Gabapentin | 29 | $299 | $10 |
| Anagrelide | 13 | $290 | $22 |
| Prednisone | 27 | $213 | $8 |
| Alendronate | 22 | $207 | $9 |
| Omeprazole | 18 | $143 | $8 |
| Zolpidem | 20 | $96 | $5 |
| Pantoprazole | 11 | $65 | $6 |
2014: 66 drugs
| Revlimid | 21 | $208,715 | $9,939 |
| Procrit | 89 | $193,423 | $2,173 |
| Avastin | 51 | $174,877 | $3,429 |
| Sprycel | 22 | $164,764 | $7,489 |
| Nexavar | 18 | $152,092 | $8,450 |
| Xgeva | 84 | $148,293 | $1,765 |
| Herceptin | 39 | $144,376 | $3,702 |
| Gleevec | 16 | $100,245 | $6,265 |
| Tasigna | 11 | $98,390 | $8,945 |
| Alimta | 17 | $81,824 | $4,813 |
| Tarceva | 14 | $80,334 | $5,738 |
| Aloxi | 110 | $60,353 | $549 |
| Nplate | 11 | $55,937 | $5,085 |
| Oxaliplatin | 45 | $47,218 | $1,049 |
| Exjade | 19 | $37,272 | $1,962 |
| Docetaxel | 13 | $18,410 | $1,416 |
| Neupogen | 13 | $16,565 | $1,274 |
| Emend | 30 | $14,280 | $476 |
| Irinotecan | 19 | $11,148 | $587 |
| Gemcitabine | 29 | $9,463 | $326 |
| Creon | 23 | $9,102 | $396 |
| Leucovorin | 48 | $8,011 | $167 |
| Hydrocodone-Acetaminophen | 127 | $6,965 | $55 |
| Exemestane | 18 | $3,992 | $222 |
| Nexium | 15 | $3,653 | $244 |
| Anastrozole | 125 | $3,388 | $27 |
| Oxycontin | 14 | $3,369 | $241 |
| Letrozole | 110 | $2,982 | $27 |
| Megestrol Acetate | 62 | $2,405 | $39 |
| Granisetron | 57 | $2,261 | $40 |
| Sodium Chloride | 250 | $1,975 | $8 |
| Carboplatin | 27 | $1,892 | $70 |
| Pamidronate Disodium | 26 | $1,642 | $63 |
| Oxycodone | 15 | $1,578 | $105 |
| Fentanyl | 18 | $1,493 | $83 |
| Fluorouracil | 47 | $1,488 | $32 |
| Cisplatin | 27 | $1,465 | $54 |
| Ondansetron | 42 | $1,328 | $32 |
| Duloxetine | 13 | $1,248 | $96 |
| Dexamethasone Sodium Phosphate | 169 | $1,112 | $7 |
| Levofloxacin | 64 | $1,075 | $17 |
| Ibandronate | 12 | $1,052 | $88 |
| Tamoxifen Citrate | 50 | $1,011 | $20 |
| Dexamethasone Sodium Phosphate | 49 | $705 | $14 |
| Amox Tr-Potassium Clavulanate | 17 | $540 | $32 |
| Hydroxyurea | 25 | $519 | $21 |
| Dexamethasone | 33 | $410 | $12 |
| Warfarin | 58 | $355 | $6 |
| Zolpidem | 40 | $340 | $9 |
| Hydromorphone | 13 | $258 | $20 |
| Omeprazole | 28 | $244 | $9 |
| Alendronate | 23 | $224 | $10 |
| Loperamide | 17 | $221 | $13 |
| Dextrose 5%-0.9% Nacl | 14 | $215 | $15 |
| Prednisone | 23 | $190 | $8 |
| Potassium Chloride | 29 | $187 | $6 |
| Magnesium Sulfate | 13 | $175 | $13 |
| Diphenhydramine | 48 | $173 | $4 |
| Gabapentin | 16 | $163 | $10 |
| Levothyroxine | 13 | $138 | $11 |
| Hydrocortisone | 15 | $122 | $8 |
| Magnesium Sulfate | 11 | $120 | $11 |
| Lorazepam | 20 | $108 | $5 |
| Calcium Gluconate | 13 | $104 | $8 |
| Ciprofloxacin | 11 | $84 | $8 |
| Furosemide | 12 | $41 | $3 |
2013: 57 drugs
| Procrit | 86 | $197,351 | $2,295 |
| Revlimid | 19 | $185,130 | $9,744 |
| Tarceva | 22 | $125,069 | $5,685 |
| Oxaliplatin | 38 | $117,249 | $3,086 |
| Avastin | 32 | $114,695 | $3,584 |
| Gleevec | 12 | $77,046 | $6,421 |
| Sprycel | 14 | $70,478 | $5,034 |
| Xgeva | 37 | $62,644 | $1,693 |
| Herceptin | 12 | $45,543 | $3,795 |
| Docetaxel | 22 | $45,501 | $2,068 |
| Exjade | 13 | $36,208 | $2,785 |
| Neupogen | 14 | $14,995 | $1,071 |
| Creon | 27 | $12,380 | $459 |
| Irinotecan | 21 | $9,979 | $475 |
| Leucovorin | 47 | $9,044 | $192 |
| Nexium | 32 | $7,269 | $227 |
| Exemestane | 20 | $4,583 | $229 |
| Emend | 12 | $4,566 | $381 |
| Anastrozole | 130 | $4,418 | $34 |
| Granisetron | 93 | $3,761 | $40 |
| Megestrol Acetate | 83 | $3,678 | $44 |
| Granisetron | 30 | $3,164 | $105 |
| Letrozole | 94 | $3,050 | $32 |
| Ibandronate | 28 | $2,717 | $97 |
| Fluorouracil | 57 | $2,127 | $37 |
| Pamidronate Disodium | 31 | $2,049 | $66 |
| Crestor | 11 | $1,882 | $171 |
| Carboplatin | 26 | $1,850 | $71 |
| Hydrocodone-Acetaminophen | 166 | $1,805 | $11 |
| Paclitaxel | 19 | $1,707 | $90 |
| Fentanyl | 22 | $1,522 | $69 |
| Amox Tr-Potassium Clavulanate | 33 | $1,288 | $39 |
| Dexamethasone Sodium Phosphate | 83 | $1,107 | $13 |
| Cisplatin | 16 | $855 | $53 |
| Levofloxacin | 61 | $794 | $13 |
| Ondansetron | 34 | $698 | $21 |
| Dexamethasone | 35 | $573 | $16 |
| Tamoxifen Citrate | 40 | $534 | $13 |
| Dexamethasone Sodium Phosphate | 74 | $530 | $7 |
| Hydroxyurea | 18 | $521 | $29 |
| Gabapentin | 31 | $516 | $17 |
| Diphenhydramine | 70 | $355 | $5 |
| Zolpidem | 45 | $234 | $5 |
| Alendronate | 27 | $228 | $8 |
| Acyclovir | 13 | $220 | $17 |
| Warfarin | 27 | $207 | $8 |
| Spironolactone | 16 | $202 | $13 |
| Prednisone | 45 | $202 | $4 |
| Omeprazole | 15 | $176 | $12 |
| Azithromycin | 18 | $171 | $9 |
| Potassium Chloride | 19 | $155 | $8 |
| Sulfamethoxazole-Trimethoprim | 19 | $125 | $7 |
| Loperamide | 14 | $118 | $8 |
| Famotidine | 13 | $115 | $9 |
| Diphenoxylate-Atropine | 12 | $100 | $8 |
| Prochlorperazine Maleate | 12 | $91 | $8 |
| Furosemide | 25 | $85 | $3 |
Money from drug and device companies
$124 in 2025
| 2025 | 4 | 4 | None | $124 |
| 2024 | 3 | 3 | None | $48 |
| 2023 | 3 | 6 | None | $102 |
| 2022 | 4 | 6 | None | $133 |
| 2021 | 2 | 11 | $2,500 | $2,620 |
| 2020 | 1 | 1 | $1,995 | $1,995 |
| 2019 | 2 | 4 | None | $73 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tempus AI | Xt Cdx | $48 | 1 payment
|
| Janssen Biotech | Rybrevant | $28 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $26 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $22 | 1 payment
|
See all 4 published payments
| Merck Sharp & Dohme | Education · 2025-12-11 | Keytruda | $26 |
| Tempus AI | Meals · 2025-11-14 | Xt Cdx | $48 |
| Janssen Biotech | Meals · 2025-06-23 | Rybrevant | $28 |
| Telix Pharmaceuticals | Meals · 2025-04-10 | Illuccix | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $48
| Merck Sharp & Dohme | Welireg | $18 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $17 | 1 payment
|
| BeiGene USA | Brukinsa | $14 | 1 payment
|
2023: $102
| Pfizer | Ibrance | $47 | 3 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $35 | 2 payments
|
| BeiGene USA | Brukinsa | $21 | 1 payment
|
2022: $133
| Pfizer | Inlyta | $64 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $33 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $19 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $18 | 1 payment
|
2021: $2,620
| Eisai | Lenvima | $2,500 | 2 payments
|
| Pfizer | Inlyta | $120 | 9 payments
|
2020: $1,995
| Eisai | Lenvima | $1,995 | 1 payment
|
2019: $73
| Allergan | Linzess | $53 | 3 payments
|
| Pfizer | Bavencio | $20 | 1 payment
|
Professional record
- NPI
- 1568581759
- Licence
- CA A95562California A95562: Current · expires 2027-11-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A955620
- Taxonomy
- Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 1520 Hollydale Dr, Fullerton, CA, 92831
- NPI first listed
- 2007-03-28
- NPI last updated
- 2026-02-18
- NPI record certified
- 2026-02-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5832 Beach Blvd Unit 201, Buena Park, CA, 90621 · 500 S Virgil Ave, Los Angeles, CA, 90020
This office lists an electronic records connection.